GAMMA Investing LLC boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1,746.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,514 shares of the company's stock after purchasing an additional 61,966 shares during the period. GAMMA Investing LLC's holdings in Roivant Sciences were worth $6,493,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Treasurer of the State of North Carolina raised its stake in Roivant Sciences by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock valued at $2,213,000 after buying an additional 1,170 shares in the last quarter. WINTON GROUP Ltd raised its stake in Roivant Sciences by 1.5% during the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock valued at $1,095,000 after buying an additional 1,332 shares in the last quarter. Covestor Ltd raised its stake in Roivant Sciences by 7.5% during the fourth quarter. Covestor Ltd now owns 20,634 shares of the company's stock valued at $245,000 after buying an additional 1,444 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after buying an additional 1,507 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in Roivant Sciences by 6.1% during the fourth quarter. Victory Capital Management Inc. now owns 27,494 shares of the company's stock valued at $325,000 after buying an additional 1,588 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Insider Buying and Selling
In related news, major shareholder Vivek Ramaswamy sold 200,800 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $11.19, for a total value of $2,246,952.00. Following the completion of the transaction, the insider now directly owns 38,426,381 shares of the company's stock, valued at $429,991,203.39. This represents a 0.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eric Venker sold 434,478 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the transaction, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. The trade was a 27.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,972,189 shares of company stock valued at $33,059,785 in the last three months. 7.90% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
ROIV has been the topic of several research reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, May 28th.
Read Our Latest Report on ROIV
Roivant Sciences Stock Performance
Shares of Roivant Sciences stock traded down $0.15 on Friday, reaching $11.32. 5,969,146 shares of the company were exchanged, compared to its average volume of 5,587,276. The company's 50-day moving average is $10.81 and its two-hundred day moving average is $10.99. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of -75.46 and a beta of 1.16. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same period last year, the company earned ($0.23) earnings per share. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
